A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease
收藏DataCite Commons2025-07-24 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002832/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
提供机构：
Vivli
创建时间：
2018-10-27
